← ANALYST RATINGS · TIPRANKS
Sanara MedTech (SMTI): analyst forecast and price target
Analyst consensus
Hold0 Buy3 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $35.00, the highest $35.00, the lowest $35.00. The average is +5.5% from the last price of $33.16.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $37.00 → $35.00−5.4% | Hold | +5.5% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $38.00 → $36.00−5.3% | Hold | +8.6% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $37.00 → $36.00−2.7% | Hold | +8.6% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $39.00 → $38.00−2.6% | Hold | +14.6% | Downgrade | 16.10.26on TipRanks 19:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $36.00 → $35.00−2.8% | Hold | +5.5% | Reiterated | 16.10.26on TipRanks 19:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $36.00 | Hold | +8.6% | Reiterated | 11.09.26on TipRanks 04:05 | — | |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $35.00 | Hold | +5.5% | Reiterated | 26.08.26on TipRanks 09:30 | −0.1%next day −0.9% · 5 days +0.6% | ↗ |
| Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% | Freedom Capital Markets | $35.00 | Hold | +5.5% | Downgrade | 03.08.26on TipRanks 10:25 | −1.0%next day −1.6% · 5 days −1.3% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $36.00 → $35.00−2.8% | Hold | +5.5% | Downgrade | 30.07.26on TipRanks 06:10 | +10.9%next day −1.3% · 5 days −3.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.00 at a price of $35.14 (−0.4%); now: $35.00 at $33.16 (+5.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 2 | 1 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 2 | 4 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.06 (from $0.02 to $0.10). Last quarter: $-0.05.
Sales
Next quarter’s sales estimate — $30M (from $29M to $30M). Last quarter: $28M.
Best top-analyst consensus in the sector · Healthcare
About Sanara MedTech
- CEO: Seth D. Yon
- Employees: 108
- 1200 Summit Avenue, Fort Worth, TX, 76102, US
- sanaramedtech.com
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗